(+)-hydromorphone

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (+)-hydromorphone
• 英文别名: (4R,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
• 化学式: C₁₇H₁₉NO₃
• 分子量: 285.343
• InChiKey: WVLOADHCBXTIJK-QEJWPVCOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+)-hydromorphone 在 sodium dithionate 、 sodium hydroxide 、 氯化铵 作用下， 反应 11.0h， 以3.3 g的产率得到6β-hydromorphol
  参考文献：
  名称：

  One Pot Process for Producing 6-Hydroxyl Nal-Opiate

  摘要：

  本发明提供了一种制备纳洛酮类药物的方法，无需分离中间体。一般来说，该方法在同一容器中进行烷基化和还原反应，从而得到纳洛酮类药物。

  公开号：

  US20130203999A1
• 作为产物：
  描述：

  (4R,4aR,7aR,12bS)-3-methyl-1,2,3,4,4a,5,6,7a-octahydrospiro[4,12-methanobenzofuro[3,2-e]isoquinoline-7,2'-[1,3]dioxolan]-9-ol 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以41 mg的产率得到(+)-hydromorphone
  参考文献：
  名称：

  蒂巴因向鸦片和其他有用中间体的转化，用于半合成阿片类药物：氢吗啡酮的合成

  摘要：

  AbstractThebaine was converted to oripavine in three steps by employing two different modes of protection of the diene moiety; as an iron tricarbonyl complex and as a Diels–Alder adduct with thioformyl cyanide. The two C‐ring‐protected thebaine derivatives were subjected to 3‐O‐demethylation by four different protocols, providing oripavine derivatives, which yielded oripavine after deprotection. Oripavine was then converted to hydromorphone by a three‐step process of ketalization, hydrogenation, and deprotection, without the isolation of intermediates.magnified image

  DOI：

  10.1002/adsc.201400445

文献信息

• Peripherally Acting Opioid Compounds
  申请人：Blumberg Laura Cook

  公开号：US20130005755A1

  公开（公告）日：2013-01-03

  The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:

  这项发明涉及公式I、II、III、IV的化合物，或其药学上可接受的酯或前药。
• PRODRUGS OF OPIOIDS AND USES THEREOF
  申请人：Franklin Richard

  公开号：US20110190267A1

  公开（公告）日：2011-08-04

  The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.

  本发明涉及阿片类镇痛药的前药以及含有此类前药的药物组合物。本发明提供了通过前述前药增加阿片类镇痛药的生物利用度，从而提供更一致的疼痛缓解方法。该发明还提供了减少阿片类镇痛药对胃肠道的副作用的方法。
• [EN] SUPPORTED METAL CATALYST FOR THE PRODUCTION OF HYDROCODONE AND HYDROMORPHONE<br/>[FR] CATALYSEUR MÉTALLIQUE SUPPORTÉ POUR LA PRODUCTION D'HYDROCODONE ET D'HYDROMORPHONE
  申请人：SIEGFRIED AG

  公开号：WO2017211879A1

  公开（公告）日：2017-12-14

  The present invention relates to the process for the manufacture of hydrocodone or hydromorphone from their enol derivatives codeine and morphine respectively. Particularly, the invention discloses a metal catalyst that is used in low amount, leads to high yields and can easily be reused.

  本发明涉及从各自的烯醇衍生物可待因和吗啡分别制造氢可酮或氢吗啡酮的过程。特别是，本发明公开了一种金属催化剂，该催化剂使用量少，可导致高产率，并且易于重复使用。
• METHOD OF PREPARING BUPRENORPHINE
  申请人：JOHNSON MATHEY PUBLIC LIMITED COMPANY

  公开号：US20140235860A1

  公开（公告）日：2014-08-21

  An improved process for preparing buprenorphine and a method for increasing the yield of buprenorphine or a derivative thereof.

  一种改进的制备丁丙诺啡的方法，以及增加丁丙诺啡或其衍生物产量的方法。
• NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF
  申请人：Franklin Richard

  公开号：US20110015182A1

  公开（公告）日：2011-01-20

  Carbamate linked prodrugs of meptazinol and other opioid analgesics are provided. The prodrug moiety may comprise a single amino acid or short peptide. Additionally, the present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid analgesic. The methods comprise orally administering an opioid prodrug or pharmaceutically acceptable salt thereof to a subject, wherein the opioid prodrug is comprised of an opioid analgesic covalently bonded through a carbamate linkage to a prodrug moiety, and wherein upon oral administration, the prodrug or pharmaceutically acceptable salt minimizes at least one gastrointestinal side effect associated with oral administration of the opioid analgesic alone. Compositions for use with the method are also provided.

  本发明提供了与咪哌唑酮和其他阿片类镇痛剂相关的氨基甲酸酯前药。前药基团可以包括单个氨基酸或短肽。此外，本发明涉及减少受试者胃肠道副作用的方法，其中胃肠道副作用与阿片类镇痛剂的给药有关。该方法包括口服给受试者阿片类前药或其药学上可接受的盐，其中阿片类前药由阿片类镇痛剂通过氨基甲酸酯键共价结合到前药基团上，且在口服给药时，前药或药学上可接受的盐至少减少与单独口服阿片类镇痛剂有关的一个胃肠道副作用。本发明还提供了用于该方法的组合物。